98 related articles for article (PubMed ID: 11519066)
21. The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients.
Miyamoto R; Inagawa S; Sano N; Tadano S; Adachi S; Yamamoto M
Eur J Surg Oncol; 2018 May; 44(5):607-612. PubMed ID: 29478743
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
Mantovani G; Macciò A; Madeddu C; Mulas C; Massa E; Astara G; Ferreli L; Mudu MC; Gramignano G; Murgia V; Lusso MR; Mocci M; Cardia A; Mura L
Oncol Rep; 2002; 9(4):887-96. PubMed ID: 12066227
[TBL] [Abstract][Full Text] [Related]
23. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
24. Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients.
Brivio F; Lissoni P; Gilardi R; Ferrante R; Vigore L; Curzi L; Uggeri F; Nespoli A; Fumagalli L
J Biol Regul Homeost Agents; 2000; 14(3):200-3. PubMed ID: 11037053
[TBL] [Abstract][Full Text] [Related]
25. Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum.
Elias D; Farace F; Triebel F; Hattchouel JM; Pignon JP; Lecesne A; Rougier P; Lasser P; Duvillard P; Escudier B
J Am Coll Surg; 1995 Oct; 181(4):303-10. PubMed ID: 7551323
[TBL] [Abstract][Full Text] [Related]
26. Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C.
Brivio F; Fumagalli L; Lissoni P; Nardone A; Nespoli L; Fattori L; Denova M; Chiarelli M; Nespoli A
Anticancer Res; 2006; 26(1B):599-603. PubMed ID: 16739327
[TBL] [Abstract][Full Text] [Related]
27. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.
Levy Y; Capitant C; Houhou S; Carriere I; Viard JP; Goujard C; Gastaut JA; Oksenhendler E; Boumsell L; Gomard E; Rabian C; Weiss L; Guillet JG; Delfraissy JF; Aboulker JP; Seligmann M
Lancet; 1999 Jun; 353(9168):1923-9. PubMed ID: 10371571
[TBL] [Abstract][Full Text] [Related]
28. [Preoperative treatment with interleukin-2 in colorectal carcinoma].
Vecchio R; Latteri F; Di Martino M; Lanteri E; Cacciola E
G Chir; 1998 Apr; 19(4):171-4. PubMed ID: 9628067
[TBL] [Abstract][Full Text] [Related]
29. A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.
Ahmed FY; Leonard GA; A'Hern R; Taylor AE; Lorentzos A; Atkinson H; Moore J; Nicolson MC; Riches PG; Gore ME
Br J Cancer; 1996 Oct; 74(7):1109-13. PubMed ID: 8855983
[TBL] [Abstract][Full Text] [Related]
30. Alteration of hypothalamus-pituitary-adrenal gland axis in colorectal cancer patients. Preliminary report.
Crippa S; Mussi C; Angelini C; Caprotti R; Bonardi C; Muselli P; Scotti M; Piacentini G; Uggeri F
Minerva Chir; 2003 Aug; 58(4):581-5. PubMed ID: 14603172
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung.
Ziegler LD; Palazzolo P; Cunningham J; Janus M; Itoh K; Hayakawa K; Hellstrom I; Hellstrom KE; Nicaise C; Dennin R
J Clin Oncol; 1992 Sep; 10(9):1470-8. PubMed ID: 1517790
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of risk factors of pulmonary infection in patients over 60 years of age after radical resection for gastric cancer].
Yao Z; Yang H; Cui M; Xing J; Zhang C; Zhang N; Chen L; Liu M; Xu K; Tan F; Su X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):164-171. PubMed ID: 30799539
[TBL] [Abstract][Full Text] [Related]
33. [Impact of preoperative lymphocyte to monocyte ratio on the prognosis of the elderly patients with stage II(-III( gastric cancer].
Cong X; Li S; Xue Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Oct; 19(10):1144-1148. PubMed ID: 27781252
[TBL] [Abstract][Full Text] [Related]
34. Preoperative vs Postoperative Eradication of Helicobacter pylori in 150 Patients with Gastric Cancer: A Randomized Controlled Trial.
Honda M; Hiki N; Nunobe S; Ohashi M; Kumagai K; Hashimoto Y; Mine S; Kamiya S; Sano T; Yamaguchi T
J Am Coll Surg; 2015 Aug; 221(2):273-9. PubMed ID: 26141464
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Klatte T; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
Folia Biol (Praha); 2003; 49(2):63-8. PubMed ID: 12779014
[TBL] [Abstract][Full Text] [Related]
36. Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.
Sano T; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Sakurai M; Takahashi H; Nakano H; Nakagawa K
Jpn J Cancer Res; 1988 Jan; 79(1):131-43. PubMed ID: 3128501
[TBL] [Abstract][Full Text] [Related]
37. Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients.
Brivio F; Lissoni P; Tisi E; Erba L; Barni S; Tancini G; Rescaldani R; Alderi G; Nociti V
Oncology; 1992; 49(3):215-8. PubMed ID: 1495748
[TBL] [Abstract][Full Text] [Related]
38. Preoperative interleukin-2 immunotherapy in pancreatic cancer: preliminary results.
Angelini C; Bovo G; Muselli P; Mussi C; Crippa S; Caprotti R; Uggeri F
Hepatogastroenterology; 2006; 53(67):141-4. PubMed ID: 16506394
[TBL] [Abstract][Full Text] [Related]
39. Preoperative administration of rebamipide significantly lowers body temperature and circulating interleukin-6 in gastric cancer patients after gastrectomy.
Shimada S; Inoue K; Kuramoto M; Suzuki S; Yamamoto K; Ogawa M
Dig Surg; 2003; 20(6):500-5. PubMed ID: 14506330
[TBL] [Abstract][Full Text] [Related]
40. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
